Ncs23766

Manufactured by Selleck Chemicals

NCS23766 is a laboratory equipment product manufactured by Selleck Chemicals. It is designed for general laboratory applications.

Automatically generated - may contain errors

Lab products found in correlation

Doxorubicin d1515, by Merck Group (1 mentions) Sch772984, by Selleck Chemicals (1 mentions) Nocodazole, by Merck Group (1 mentions) D9891, by Merck Group (1 mentions) Cc 2517, by Lonza (1 mentions) Taxol, by Merck Group (1 mentions) Cc 2512, by Lonza (1 mentions) P9620, by Merck Group (1 mentions) Plix 402, by Addgene (1 mentions) Ck 666, by Merck Group (1 mentions)

2 protocols using ncs23766

Synthesis and Characterization of DDP Prodrug

Check if the same lab product or an alternative is used in the 5 most similar protocols

DDP (P3494) and doxorubicin (D1515) were purchased from Sigma. Docetaxel (T1034) was purchased from TargetMol. Carboplatin (C805203) was purchased from Macklin, ERK inhibitor SCH772984 and Rac1 inhibitor NCS23766 was from Selleck.
The DDP prodrug was synthesized according previous report^{51 (link)}, by using the reaction between cis, trans, cis-[PtCl₂(OH)₂(NH₃)₂], and sebacic anhydride. The structure of this DDP prodrug was analyzed by proton nuclear magnetic resonance (HNMR) to confirm successful synthesis (Supplementary Fig. 8). Details of the drugs including their targets and concentrations noted in the figure legends.

Li Q., Qin T., Bi Z., Hong H., Ding L., Chen J., Wu W., Lin X., Fu W., Zheng F., Yao Y., Luo M.L., Saw P.E., Wulf G.M., Xu X., Song E., Yao H, & Hu H. (2020). Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nature Communications, 11, 1456.

+ Open protocol

+ Expand

Inducible Protein Expression in HUVECs

Check if the same lab product or an alternative is used in the 5 most similar protocols

HUVECs (CC-2517; Lonza, Houston, TX) and human lung fibroblasts (CC-2512; Lonza) were maintained at 37°C with 5% CO₂ and grown under standard conditions. Rac1-GTPase inhibitor (NCS-23766; SelleckChem, Boston, MA) was at 100 μM, and Arp2/3 inhibitor (CK-666; Sigma-Aldrich, St. Louis, MO) was at 10 μM. Nocodazole (M1404; Sigma-Aldrich) and Taxol (T7402; Sigma-Aldrich) were used at indicated concentrations. Stable HUVEC populations were generated by inserting relevant transgenes into pLIX_402 (41394; Addgene, Cambridge, MA), a Gateway-compatible Tet-On lentivirus. P2 HUVECs were transfected with the pLIX virus, and puromycin at 2 μg/ml (P9620; Sigma-Aldrich) was added 4 d later. After 2 d, puromycin was added at 4 μg/ml. When HUVECs reached confluency, they were split 1:10 and frozen in liquid N₂. Transgene expression was induced by overnight incubation with DOX (D9891; Sigma-Aldrich). For all experiments except the sprouting angiogenesis assay (described later), cells were assessed within 24 h of DOX treatment, and ECs with nuclear sizes <50% of median or ≥200% of median size were excluded from analysis.

Kushner E.J., Ferro L.S., Yu Z, & Bautch V.L. (2016). Excess centrosomes perturb dynamic endothelial cell repolarization during blood vessel formation. Molecular Biology of the Cell, 27(12), 1911-1920.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!